Technology
Health
Biotechnology

Xenetic

$2.11
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (2.00%) Today
+$0.07 (3.43%) After Hours

Why Robinhood?

You can buy or sell Xenetic and other stocks, options, ETFs, and crypto commission-free!

About

Xenetic Biosciences, Inc. Common Stock, also called Xenetic, is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of next generation biologic drugs and novel orphan oncology therapeutics. Read More Its lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod), which focuses on the treatment of progesterone resistant endometrial cancer. It also offers proprietary drug development platform, PolyXen, which enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company was founded on August 9, 2011 and is headquartered in Lexington, MA.

Employees
5
Headquarters
Lexington, Massachusetts
Founded
2011
Market Cap
19.18M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
247.44K
High Today
$2.13
Low Today
$2.00
Open Price
$2.04
Volume
23.28K
52 Week High
$8.95
52 Week Low
$1.37

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Research And Development
Therapy
Cancer Prevention

Earnings

-$0.34
-$0.05
$0.23
$0.52
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Mar 28, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.